|
|
1.
|
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. MedStar authors:
Year: 2018
Citation: - Diabetes Care. 41(2):258-266, 2018 02.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Ahmann AJ, Annett MP, Aroda VR, Capehorn M, Charpentier G, Dotta F, Henkel E, Holst AG, Lingvay I
|
|
|
2.
|
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). MedStar authors:
Year: 2017
Citation: - Diabetic Medicine. 34(12):1747-1755, 2017 Dec.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Knowler WC, Mather KJ, Pan Q, Perreault L, The Diabetes Prevention Program Research Group
|
